Myeloma Cancer Breakthrough News
|
|
Dec
11, 2007
ASH: Low-Dose Steroid Combo Bests High-Dose Regimen
in Multiple Myeloma |
|
|
By Charles Bankhead,
Staff Writer, MedPage Today
ATLANTA, Dec. 11 --
Two-year survival in newly diagnosed multiple
myeloma patients improved significantly when
lenalidomide (Revlimid) was given with low-dose
dexamethasone rather than standard high-dose steroid
therapy, according to updated results of a
multicenter clinical trial. <READ
MORE> |
|
|
|
|
Nov 21, 2007
Lenalidomide Benefits in Recurrent Myeloma Detailed |
|
|
By Charles Bankhead,
Staff Writer, MedPage Today
HOUSTON, Nov. 21 --
Patients with relapsed or refractory multiple
myeloma had significantly improved progression-free
and overall survival when treated with lenalidomide
(Revlimid) and dexamethasone, compared with
dexamethasone and placebo. <READ
MORE> |
|
|
|
|
Oct
20, 2007
Webcast of Presentation at "Lymphoma & Myeloma 2007"
held in New York, NY. |
|
|
By
Ruben Niesvizky,
MD
Emerging therapeutic
strategies for multiple myeloma: Proteasome
inhibitors and immunomodulators
<CLICK
HERE TO VIEW WEBCAST> |
|
|
|
|
|
|
